



OPEN

Clusters of risk factors in metabolic syndrome and their influence on central blood pressure in a global study

Agne Laucyte-Cibulskiene^{1✉}, Chen-Huan Chen², John Cockroft³, Pedro G. Cunha^{4,5}, Maryam Kavousi⁶, Aleksandras Laucevicius⁷, Maria Lorenza Muiesan⁸, Ernst R. Rietzschel⁹, Ligita Ryliskyte⁷, Irina D. Strazhesko¹⁰, Charalambos Vlachopoulos¹¹, Jorge Cotter⁵, Ekatherina N. Dudinskaya¹⁰, Nichola Gale¹², Fariba Ahmadizar⁶, Francesco U. S. Mattace-Raso¹³, Maggie Munnerly³, Pedro Oliveira¹⁴, Anna Paini⁸, Massimo Salvetti⁸, Olga N. Tkacheva¹⁰, Edward G. Lakatta¹⁵, Peter M. Nilsson¹⁶ & Angelo Scuteri¹⁷

The effect of metabolic syndrome (MetS) and clusters of its components on central blood pressure (CBP) has not been well characterized. We aimed to describe the effect of MetS and clusters of its components on CBP in a large population and to identify whether this effect differs in men and women. We studied 15,609 volunteers (43% women) from 10 cohorts worldwide who participated in the Metabolic syndrome and Artery REsearch Consortium. MetS was defined according to the NCEP-ATP III criteria (*GHTBW*, glucose, high-density lipoprotein cholesterol, triglyceride, blood pressure, waist circumference). CBP was measured noninvasively and acquired from pulse wave analysis by applanation tonometry. MetS was associated with a 50% greater odds of having higher CSBP. After controlling for age, male sex, non HDL cholesterol, diabetes mellitus, and mean arterial pressure, only specific clusters of MetS components were associated with a higher CSBP; and some of them were significant in women but not in men. We identified “risky clusters” of MetS variables associated with high CSBP. Future studies are needed to confirm they identify subjects at high risk of accelerated arterial aging and, thus, need more intensive clinical management.

Brachial blood pressure measurement is the most widely used approach in managing hypertension in daily clinical practice. Many epidemiological and interventional studies showed an undeniable beneficial effect of lowering brachial blood pressure for cardiovascular (CV) and renal outcomes¹. However, the accuracy of peripheral systolic and diastolic blood pressure in reflecting central blood pressure has been questioned since 2007². This challenge

¹Department of Clinical Sciences, and Department of Nephrology, Lund University, Ruth Lunds kogs gata 14, S-214 28 Malmö, Sweden. ²Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan. ³Cardiff Metropolitan University, Cardiff, UK. ⁴Center for the Research and Treatment of Arterial Hypertension and Cardiovascular Risk, Internal Medicine Department, Guimarães, Portugal. ⁵Life and Health Research Institute (ICVS/3B's), Minho University, Braga, Portugal. ⁶Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands. ⁷Faculty of Medicine, Vilnius University, Vilnius University Hospital Santaros Klinikos, State Research Institute Centre of Innovative Medicine, Vilnius, Lithuania. ⁸Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. ⁹Ghent University Hospital, Ghent, Belgium. ¹⁰The Stand-Alone Structural Unit of the Pirogov Russian National Research Medical University, the “Russian Clinical Research Center for Gerontology” of the Ministry of Healthcare of the Russian Federation, Moscow, Russia. ¹¹1st Department of Cardiology, National and Kapodistrian University of Athens, Athens, Greece. ¹²School of Healthcare Sciences, College of Biomedical and Life Sciences, Cardiff, UK. ¹³Department of Geriatrics, Erasmus MC University Hospital Rotterdam, Rotterdam, The Netherlands. ¹⁴Departamento de Estudo de Populações, Instituto de Ciências Biomédicas Abel Salazar, Universidade Do Porto, Porto, Portugal. ¹⁵Laboratory of Cardiovascular Sciences, National Institute on Aging – National Institutes of Health, Baltimore, USA. ¹⁶Department of Clinical Sciences, Lund University, Malmö, Sweden. ¹⁷Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. ✉email: agne.laucyte-cibulskiene@med.lu.se

has paralleled the increasing attention to large arteries. Indeed, recent research has focused on accelerated to healthy/supernormal vascular aging^{3–5} and the possible role of vascular geometry⁶; aortic stiffness as an independent predictor of cardiovascular morbidity⁷ and its association with the progression of cognitive impairment⁸ and multiple organ damage^{9–11}; the definition of a “normality threshold” for clinical purposes¹² and the role of arterial aging in response to treatment¹³; and the issue of central blood pressure in routine clinical practice¹⁴.

Whereas mean arterial pressure (MBP) and diastolic blood pressure (DBP) are relatively constant along the arterial tree, the height of the pressure pulse is amplified from the aorta toward peripheral arteries¹⁵. Therefore, brachial SBP is higher than central systolic blood pressure (CSBP). These differences decrease with advancing age and are affected by sex, body height, and cardiovascular risk factors (e.g., dyslipidemia, diabetes, and smoking)¹⁶.

As peripheral tissues to central (aortic) rather than brachial pressures, CBP has shown a stronger association with left ventricular hypertrophy, intima-media thickness, and pulse wave velocity¹⁷. And CBP was a stronger predictor of CV events than brachial BP^{18–20}. Moreover, interventional studies showed that specific antihypertensive drug treatment differentially impacts on brachial and CSBP^{21,22}.

Metabolic syndrome (MetS) is a complex construct encompassing several clusters of five components (low HDL cholesterol, increased fasting glucose, increased triglyceride, elevated waist circumference, and elevated peripheral blood pressure). The effects of MetS and the selected cluster of MetS components on large artery stiffness and thickness have been described in a previous report from the MARE Consortium²³. However, the effect of MetS and clusters of MetS components on CBP has not yet been described in large populations.

The present cross-sectional, observational study aims to describe the association between MetS and selected clusters of its components on CBP in a large global population and identify possible sex differences in this association.

Subjects and methods

The MARE consortium. The original MARE (Metabolic Syndrome and Artery Research) Consortium aimed to identify diverse metabolic syndrome clusters and their association with vascular aging, gene-lifestyle interactions, and cardiovascular risk among ten cohort studies worldwide and to develop novel cardiovascular prevention methods based on lifestyle modification. The detailed methodology is published elsewhere²³. The MARE Consortium is open to additional participating cohorts if data on the MetS components and arterial properties become available for the recruited subjects. The affiliates providing data for the present study are described in Appendix 1 and include subjects from Belgium, Portugal, Greece, Taiwan, Lithuania, Sweden, Russia, the Netherlands, and Italy. All participating countries provided approval for this study.

The ethical committee approved this international multicenter study of Ghent University Hospital and the University of Pennsylvania Institutional Review Board; the Committee of ethics of research with the medicine of the health area of Salamanca; the Ethics committee for the health of Guimaraes; the Ethics Committee of the Athens Medical School; Yu-li Veterans Hospital Ethics Committee; the Vilnius Regional Bioethics Committee of Clinical Research; the Ethical Committee at the Lund University; The ethics committee of the National Research Centre for Preventive Medicine in Moscow; The Medical Ethics Committee of Erasmus University; Bro Taf Local Research Ethics Committee in Cardiff; by the institutional Ethical Committee on human research of the University of Brescia (details provided in Appendix 1).

Each subject gave informed consent.

The MARE Consortium was performed in line with the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, Revised November 13, 2001, effective December 13, 2001. All methods of this study were performed following the relevant guidelines and regulations stated in the Declaration of Helsinki.

Definition of the metabolic syndrome. MetS was defined according to The Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP ATP III)²⁴ criteria, where the metabolic syndrome is diagnosed if three or more of the following five components are present:

- (1) Elevated fasting glucose (G) (≥ 110 mg/dl) or the presence of drug treatment for increased glucose;
- (2) Low HDL cholesterol (H) (< 40 mg/dl in men and < 50 mg/dl in women) or the presence of a specific treatment for lipid abnormalities;
- (3) High triglycerides (T) (≥ 150 mg/dl) or the presence of a particular treatment for lipid abnormalities;
- (4) Elevated blood pressure (systolic or diastolic, ≥ 130 or ≥ 85 mmHg) (B) or presence of antihypertensive treatment;
- (5) Abdominal obesity (W) with a waist circumference of more than 102 cm in men and more than 88 cm in women.

Since at least three components define metabolic syndrome, the study subjects could have had 16 different MetS component combinations.

Brachial and central blood pressure measurements. Brachial blood pressure (BP) was measured according to European Society of Hypertension recommendations²⁵. Pulse pressure (PP) was determined as systolic BP minus diastolic BP in mmHg. Mean arterial pressure (MBP) calculated as diastolic BP + 1/3 (PP).

After resting for 10 min in the supine position, central blood pressure was measured noninvasively and acquired from pulse wave analysis by applanation tonometry (SphygmoCor, AtCor Medical Pty Ltd, Sydney,

Variable	N	Value
Age, years	15,609	59 (14)
Sex (men)	15,609	57% (8897)
MI	9245	5.8% (536)
Stroke	8767	3.4% (298)
Hypertension	12,168	55% (6692)
Diabetes mellitus	15,035	12% (1804)
Smoking	15,490	50% (7745)
Antihypertensive treatment, yes	11,314	24% (2715)
Andiabetic treatment, yes	7931	7.9% (626)
Lipid lowering drugs, yes	11,565	17% (1966)
Brachial SBP, mmHg	15,609	136 (20)
Brachial DBP, mmHg	15,609	79 (11)
Brachial PP, mmHg	15,609	57 (16)
Mean arterial blood pressure, mmHg	15,609	98 (13)
Central SBP	15,609	130 (21)
Central PP, mmHg	15,609	50 (17)
Heart rate, bpm	13,196	70 (12)
BMI, kg/m ²	13,995	27.4 (4.8)
Waist circumference, cm	15,503	93 (13)
Total cholesterol mg/dL/mmol/L	15,303	217 (47)/5.6 (1.2)
High density cholesterol, mg/dL/mmol/L	15,236	57 (19)/1.5 (0.5)
Triglycerides, mg/dL/mmol/L	15,205	121 (108)/1.4 (1.2)
Glucose, mg/dL/mmol/L	14,078	101 (25)/5.6 (1.4)
Creatinine, mg/dL/mkmol/L	14,692	0.88 (0.24)/78 (21)
cfPWV, m/s	15,609	9.9 (3.3)
CCA IMT, mm	10,957	817 (227)

Table 1. Characteristics of the study cohorts from the MARE Consortium. Data are presented as the average (SD) for continuous measures and percentage (n) for categorical measures. Abbreviations: BMI, body mass index; MI, myocardial infarction; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; CCA IMT, common carotid artery intima-media thickness; cfPWV, carotid-femoral pulse wave velocity.

Australia) at the femoral artery or common carotid artery. The heart rate was monitored using three-lead electrocardiography. All measurements were performed by a trained operator three times in a row; the goal operator index was considered greater than 80%. Only measurements that fulfilled these requirements were analyzed. Elevated central systolic BP was defined as higher than or equal to 140 mmHg.

The gold standard method for CBP is invasive measurement. According to the previous reports²⁶, the applanation tonometry derived CBP overestimates the invasively measured CBP by 0.3 ± 1.0 mmHg.

Statistical analysis. All analyses were performed using the SAS package for Windows (9.1 Version Cary, NC, US). ANOVA followed by the Bonferroni test was adopted to compare means among subgroups of subjects. Least square means (\pm standard error, SEM) were calculated with ANCOVA analysis to compare CSBP, CPP, and pulse pressure amplification (PPA) values and to compare CSBP values across clusters of MetS components after controlling for covariates (age, sex, non HDL cholesterol (nonHDL-C) levels, MBP, presence of diabetes mellitus). To test for possible age- or sex-specific differences in CSBP and CPP across MetS clusters, interaction terms for sex, age, and MetS clusters were alternatively introduced into separate models.

Multivariable logistic regression models were constructed to identify potential clusters of MetS components associated with high CSBP (≥ 140 mmHg).

A two-sided p-value < 0.05 indicated statistical significance.

Results

The characteristics of the 15,609 participants (43% women) from cohorts participating in the MARE consortium are illustrated in Table 1. CPP, but not CSBP, was significantly greater in women than in men (51 ± 18 vs. 49 ± 17 mmHg, $p < 0.001$).

Effects of specific clusters of MetS components on CSBP. Both CSBP and CPP levels progressively increased with the number of altered MetS components (Fig. 1).

In the model including age, sex, brachial SBP and DBP, and use of antihypertensive medications, MetS was associated with a 50% greater odds of having high CSB (OR 1.50; 95% CI: 1.38–1.63, $p < 0.001$).




Figure 1. Central systolic blood pressure and pulse pressure values according to the number of altered MetS components. Men—black bars, women—gray bars. Numbers from 0 to 5 indicate the numbers of MetS components. Significant sex-specific differences in CSBP ($p < 0.001$) and in CPP ($p < 0.001$). Three components or more are considered typical of MetS.

Then we tried to identify specific clusters of MetS components associated with higher CSBP, as previously illustrated for large artery stiffness and thickness. As expected, a cluster of MetS components with elevated brachial BP had higher CSBP and CPP levels (data not shown) than those MetS clusters without elevated BP levels. Therefore, to account for differences in brachial BP levels, glucose, and lipid levels according to the cluster of MetS components, multivariable logistic regression models were constructed, including non HDL-C, MBP, and presence of diabetes mellitus—together with age and sex—as covariates; and controlling for age, male sex, nonHDL-C, MBP, and presence of diabetes mellitus.


Except for *low HDL-C-hypertriglyceridemia-abdominal obesity* (HTW), the other combinations of MetS components were accompanied by a 1.3 to a 4.0 fold greater odds of presenting high CSBP (Fig. 2). Of note, in addition to HTW, HBW and GHBW MetS clusters were not associated with greater CSBP levels in men but not in women (Fig. 2 bottom panels).

Secondary analyses, run after excluding participants using antihypertensive medications, showed that the cluster of MetS components TBW (OR 1.52, 95% CI 1.05–2.20), HTB (OR 1.85, 95% CI 1.15–2.97), and GHTBW (OR 3.40, 95% CI 1.99–5.81) were associated with higher CSBP after controlling for age, sex, diabetes, non HDL cholesterol, and MBP levels.


Discussion

The present cross-sectional, observational study showed that MetS was associated with greater odds of having higher CSBP, independent of age, sex, and brachial blood pressure levels. However, not all the clusters of MetS components defining “the metabolic syndrome” were associated with high CSBP, and sex-differences were observed in the specific MetS clusters associated with high CSBP.

All subjects



Men



Women




Figure 2. Clusters of MetS components as determinants of high CSBP—controlling for age, diabetes mellitus, nonHDL-C, and mean blood pressure. Odds ratio (OR) with 95% confidence interval for specific MetS clusters of components in the whole population (upper panel), in men (central panel), and women (lower panel). We evaluated all the possible combinations of MetS components, but only specific clusters are described here. Abbreviations: All other MetS comb., all different combinations of metabolic syndrome components not depicted in the picture; MetS, metabolic syndrome; W, abdominal obesity; H, low HDL cholesterol; B, high blood pressure; T, triglycerides; G, glucose; MAP, mean arterial pressure. Not significant clusters in men: *HTW*, *HBW*, *GHBW*; in women: *HTW*; in the whole population: *HTW*.

Large arteries are heterogeneous, and their functional and structural properties are poorly correlated with each other^{27,28}. Measures of large artery structure and function as markers of vascular aging have emerged as independent predictors of CV morbidity and related disability²⁹.

Notably, specific clusters of MetS components—namely HBW, TBW, and GBW—have been constantly associated with greater odds not only of high CSBP but also of stiffer²³ and thicker²⁹ arteries.

Given the cross sectional-nature of the MARE Consortium, including large population studies, we can only speculate about potential pathophysiological mechanisms underlying our findings.

The first interpretation—identifying a bias rather than a finding—may suggest that MetS clusters, including the “elevated (brachial) blood pressure” (B) component, carried greater odds of having high CSBP simply because of the high correlation between brachial and central SBP levels.

Though we cannot rule out this interpretation, it does not seem to represent the most accurate explanation. When subjects receiving antihypertensive treatment were excluded, not all the MetS clusters, including the “elevated (brachial) blood pressure” (B) component, were associated with significantly greater odds of having high CSBP.

Additionally, in men, specific MetS clusters, including elevated brachial blood pressure (HBW and GHBW), were not associated with greater odds of having high CSBP.

Furthermore, a significant association between HTW and high CSBP had been expected, but it has not been observed in the present study. In fact, visceral adiposity has been associated with a fivefold higher risk of hypertension³⁰. Recently, the adipose tissue has emerged as an endocrine organ, secreting adipokines (adiponectin, pectin, etc.) with a systemic impact on the cardiac and vascular system. Lower adiponectin levels were observed in the presence of higher ambulatory 24-h blood pressure in the *Porto Alegre* cohort³¹. Lower adiponectin levels have been associated with stiffer arteries independently of MetS components in the SardiNIA Study³² and hypertensive subjects with MetS³³. Adipose tissue also expresses mineralocorticoid receptors, modulating vascular remodeling, development of glucose tolerance, and obesity³⁴.

A relevant unanswered question remains whether these clusters recognize a common altered pathway of pathophysiological relevance—with or without a genetic basis—remains speculative to date. However, these MetS clusters likely identify subjects with accelerated arterial aging, at greater risk of CV mortality and disability, and, thus, need a more intensive management.

Despite ongoing research collaborations and activities in gender-related science, further research is needed to analyze the sex-specific interplay between MetS and central hemodynamics. Two decades ago³⁵, different large artery properties showed elevated CBP in men younger than 40 years compared to women. The Bogalusa Heart Study³⁶ observed a more pronounced discrepancy between peripheral and central blood pressure in women than in men. The SardiNIA Study reported a stronger association of visceral obesity with arterial stiffness in women than in men³⁷. Gender differences have also been reported for genetic markers of visceral adiposity³⁸. We also report a steeper CSBP slope with age in women than in men, with a turning point at 50 years of age, after which the difference disappears. Our study observed higher CPP in women not dependent on MetS components such as elevated brachial blood pressure and abdominal obesity.

Yet, the sex-specific differences in central hemodynamics in the context of MetS still need clarification.

One limitation of this study is represented by its cross-sectional design. Additionally, no information on antihypertensive drug classes was universally coded and available for participants from all MARE Consortium cohorts.

This multicenter, multiethnic observational study confirms that the greater odds of having high CSBP associated with the presence of MetS hides a constellation of phenotypes that are not equally risky of arterial aging, whether indexed as central BP, large artery stiffness, or thickness.

Identification of “risky clusters” in the whole population and specific to sex may contribute to a more personalized management of CV risk and lead to the identification of novel pathways accelerating arterial aging.

Further studies are needed to elucidate the sex-specific interplay between MetS components and the pathophysiology of vascular aging.

Received: 20 October 2021; Accepted: 5 August 2022

Published online: 24 August 2022

References

- Xie, X. *et al.* Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: Updated systematic review and meta-analysis. *Lancet* **387**, 435–443 (2016).
- Mancia, G. *et al.* 2007 Guidelines for the management of arterial hypertension. *Eur. Heart J.* **28**, 1462–1536 (2007).
- Calimport, S. R. G. *et al.* To help aging populations, classify organismal senescence. *Science* **1979**(366), 576–578 (2019).
- Nilsson, P. M. *et al.* Characteristics of healthy vascular ageing in pooled population-based cohort studies: The global metabolic syndrome and artery research consortium. *J. Hypertens.* **36**, 2340–2349 (2018).
- Cunha, P. G. *et al.* Pulse wave velocity distribution in a cohort study: From arterial stiffness to early vascular aging. *J. Hypertens.* **33**, 1438–1445 (2015).
- Scuteri, A. *et al.* Functional correlates of central arterial geometric phenotypes. in *Hypertension* vol. 38 1471–1475 (Lippincott Williams and Wilkins, 2001).
- Vlachopoulos, C., Aznaouridis, K. & Stefanadis, C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis. *J. Am. Coll. Cardiol.* **55**, 1318–1327 (2010).
- Scuteri, A. & Wang, H. Pulse wave velocity as a marker of cognitive impairment in the elderly. *J. Alzheimer's Dis.* **42**, S401–S410 (2014).
- Scuteri, A. *et al.* Arterial stiffness and multiple organ damage: A longitudinal study in population. *Aging Clin. Exp. Res.* <https://doi.org/10.1007/s40520-019-01260-0> (2019).

10. Scuteri, A. *et al.* An operational definition of SHATS (Systemic Hemodynamic Atherosclerotic Syndrome): Role of arterial stiffness and blood pressure variability in elderly hypertensive subjects. *Int. J. Cardiol.* **263**, 132–137 (2018).
11. Scuteri, A. *et al.* Routine assessment of cognitive function in older patients with hypertension seen by primary care physicians: Why and how—a decision-making support from the working group on “hypertension and the brain” of the European Society of Hypertension and from the European Geriatric Medicine Society. *J. Hypertens* **39**, 90–100 (2021).
12. Mattace-Raso, F. U. S. *et al.* Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘Establishing normal and reference values’. *Eur. Heart J.* **31**, 2338–2350 (2010).
13. Lakatta, E. G. *et al.* Impact of Stiffer Arteries on the Response to Antihypertensive Treatment: A Longitudinal Study of the SardiNIA Cohort. *J. Am. Med. Dir. Assoc.* **21**, 720–725 (2020).
14. Sharman, J. E. *et al.* Lancet Commission on Hypertension group position statement on the global improvement of accuracy standards for devices that measure blood pressure. *J. Hypertens.* **38**, 21–29 (2020).
15. Pauca, A. L., Wallenhaupt, S. L., Kon, N. D. & Tucker, W. Y. Does radial artery pressure accurately reflect aortic pressure?. *Chest* **102**, 1193–1198 (1992).
16. Herbert, A., Cruickshank, J. K., Laurent, S. & Boutouyrie, P. Reference Values for Arterial Measurements Collaboration: Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. *Eur. Heart J.* **35**, 3122–3133 (2014).
17. Kollias, A., Lagou, S., Zeniodi, M. E., Boubouchairpoulou, N. & Stergiou, G. S. Association of central versus brachial blood pressure with target-organ damage: Systematic review and meta-analysis. *Hypertension* **67**, 183–190 (2016).
18. Roman, M. J. *et al.* Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: The Strong Heart Study. *Hypertension* **50**, 197–203 (2007).
19. Pini, R. *et al.* Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARE Dicomano Study. *J. Am. Coll. Cardiol.* **51**, 2432–2439 (2008).
20. Wang, K. L. *et al.* Central or peripheral systolic or pulse pressure: Which best relates to target organs and future mortality?. *J. Hypertens.* **27**, 461–467 (2009).
21. Williams, B., *et al.*; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation.* **113**, 1213–1225 (2006).
22. Boutouyrie, P., Achouba, A., Trunet, P., Laurent, S., & EXPLOR Trialist Group. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: The EXPLOR study. *Hypertension.* **55**, 1314–1322 (2010).
23. Scuteri, A. *et al.* Arterial stiffness and influences of the metabolic syndrome: A cross-countries study. *Atherosclerosis* **233**, 654–660 (2014).
24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA: J. Am. Med. Assoc.* **285**, 2486–2497 (2001).
25. O’Brien, E. *et al.* European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. *J. Hypertens.* **21**(5), 821–848 (2003).
26. Kang, J. H. *et al.* A comparison between central blood pressure values obtained by the Gaon system and the SphygmoCor system. *Hypertens Res* **35**, 329–333 (2012).
27. Prado, C. M. & Rossi, M. A. Circumferential wall tension due to hypertension plays a pivotal role in aorta remodeling. *Int. J. Exp. Pathol.* **87**, 425–436 (2006).
28. Carallo, C. *et al.* Evaluation of common carotid hemodynamic forces: Relations with wall thickening. *Hypertension* **34**, 217–221 (1999).
29. Scuteri, A. *et al.* The relationship between the metabolic syndrome and arterial wall thickness: A mosaic still to be interpreted. *Atherosclerosis* **255**, 11–16 (2016).
30. Hayashi, T. *et al.* Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. *Ann. Intern. Med.* **140**, 1 (2004).
31. von Frankenberg, A. D. *et al.* Major components of metabolic syndrome and adiponectin levels: A cross-sectional study. *Diabetol. Metab. Syndr.* **6**, 1 (2014).
32. Scuteri, A. *et al.* Independent and additive effects of cytokine patterns and the metabolic syndrome on arterial aging in the SardiNIA Study. *Atherosclerosis* **215**(2), 459–464 (2011).
33. Chen, M. C. *et al.* Low serum adiponectin level is associated with metabolic syndrome and is an independent marker of peripheral arterial stiffness in hypertensive patients. *Diabetol. Metab. Syndr.* **9**, 49 (2017).
34. Feraco, A. *et al.* Mineralocorticoid receptors in metabolic syndrome: From physiology to disease. *Trends Endocrinol. Metab.* **31**(3), 205–217 (2020).
35. Hayward, C. S. & Kelly, R. P. Gender-related differences in the central arterial pressure waveform. *J. Am. Coll. Cardiol.* **30**, 1863–1871 (1997).
36. Chester, R. *et al.* Women have significantly greater difference between central and peripheral arterial pressure compared with men: The Bogalusa Heart Study. *J. Am. Soc. Hypertens.* **7**, 379–385 (2013).
37. Scuteri, A. *et al.* Associations of large artery structure and function with adiposity: Effects of age, gender, and hypertension. The SardiNIA Study. *Atherosclerosis* **221**(1), 189–197 (2012).
38. Fox, C. S. *et al.* Genome-wide association for abdominal subcutaneous and visceral adipose reveals a novel locus for visceral fat in women. *PLoS Genet* **8**(5), e1002695 (2012).

Acknowledgements

We thank all the participants in the cohorts for contributing data to the MARE consortium and the funding agencies supporting these cohorts.

Author contributions

All authors contributed to the study design. A.L.-C. and A.S. analyzed the data. A.L.-C. and A.S. drafted the manuscript. All authors critically revised the manuscript and read and approved the final version.

Funding

Open access funding provided by Lund University. The Asklepios Study is supported by the Fund for Scientific Research—Flanders (FWO research grants G042703 and G083810N). The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research; the Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Netherlands Heart Foundation; the Ministry of Education, Culture

and Science; the Ministry of Health Welfare and Sports; the European Commission; and the Municipality of Rotterdam. The SardiNIA team was supported by Contract NO1-AG-1-2109 from the NIA. This research was partly supported by the Intramural Research Program of the NIH, National Institute on Aging (USA). The LitHiR program was reimbursed from the Statutory Health Insurance Fund (Lithuania). The Malmö Diet and Cancer Study (MDCS) has been supported by a Lund University Infrastructure grant “Malmö population-based cohorts” (STYR 2019/2046). The SMART study was funded initially by Takeda. The Vobarno Study is supported by grants from the European Community Network of Excellence (InGenious HyperCare, 2006 to 2010); Italian University and Research Ministry, Regione Lombardia, and Fondazione della Comunità Bresciana Onlus.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-022-18094-y>.

Correspondence and requests for materials should be addressed to A.L.-C.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022

Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com